Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre J Lefèbvre

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Lancet. Diabetes & Endocrinology|December 25, 2022
Glucagon, from past to present: a century of intensive research and controversiesAndré J Scheen, Pierre J Lefèbvre
European Journal of Pharmacology|November 22, 2005
Does insulin release kinins in rats?Jacques Damas, Nancy Garbacki, Pierre J Lefèbvre
Expert Opinion on Investigational Drugs|October 21, 2017
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetesAndré J Scheen, Nicolas Paquot, Pierre J Lefèbvre
Obesity Research|March 12, 2002
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patientsNicolas Paquot, André J Scheen, Mirjam Dirlewanger, et al.
Lancet (London, England)|October 11, 2005
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialJohn A Dormandy, Bernard Charbonnel, David J A Eckland, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Lancet. Diabetes & Endocrinology|December 25, 2022
Glucagon, from past to present: a century of intensive research and controversiesAndré J Scheen, Pierre J Lefèbvre
European Journal of Pharmacology|November 22, 2005
Does insulin release kinins in rats?Jacques Damas, Nancy Garbacki, Pierre J Lefèbvre
Expert Opinion on Investigational Drugs|October 21, 2017
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetesAndré J Scheen, Nicolas Paquot, Pierre J Lefèbvre
Obesity Research|March 12, 2002
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patientsNicolas Paquot, André J Scheen, Mirjam Dirlewanger, et al.
Lancet (London, England)|October 11, 2005
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialJohn A Dormandy, Bernard Charbonnel, David J A Eckland, et al.
Pageof 1